Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Am Soc Clin Oncol Educ Book. 2020 Mar;40:1–12. doi: 10.1200/EDBK_280807
71 yr old female
Presented with shortness of breath
Past medical history – high blood pressure, ischemic heart disease 10 years ago
WHO PS1
PFT- FEV1 80% predicted; KCO 105% predicted
CT thorax abdomen – right upper lobe tumor & enlarged station 4R, 7 lymph nodes T3 N2 M0
Mediastinoscopy - Station 4R adenocarcinoma PDL1 10%
PET-CT - FDG avid right supraclavicular lymph node T3 N3 M0
MR Brain - Clear
Treatment – IMRT 66 Gy in 33 fractions, concurrently with cisplatin etoposide x 2 cycles starting day 1 of radiotherapy
2 weeks post CTRT
CTCAE v5.0 Grade 3 oesophagitis, PS2
4 weeks post CTRT
CTCAE v5.0 Grade 2 oesophagitis, PS1
Decision to start durvalumab 5 weeks after completion of CRT for a duration of 12 months